WallStSmart

AC Immune Ltd (ACIU)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AC Immune Ltd generates 2260% more annual revenue ($17.51M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -246.5%. RVMD earns a higher WallStSmart Score of 24/100 (F).

ACIU

Avoid

24

out of 100

Grade: F

Growth: 5.3Profit: 3.0Value: 5.0Quality: 4.5
Piotroski: 2/9Altman Z: -5.20

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ACIU2 strengths · Avg: 9.5/10
Revenue GrowthGrowth
1057.0%10/10

Revenue surging 1057.0% year-over-year

Debt/EquityHealth
0.129/10

Conservative balance sheet, low leverage

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

Areas to Watch

ACIU4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$274.42M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-210.0%2/10

ROE of -210.0% — below average capital efficiency

RVMD4 concerns · Avg: 3.5/10
Price/BookValuation
15.7x4/10

Trading at 15.7x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : ACIU

The strongest argument for ACIU centers on Revenue Growth, Debt/Equity. Revenue growth of 1057.0% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : ACIU

The primary concerns for ACIU are EPS Growth, Market Cap, Piotroski F-Score.

Bear Case : RVMD

The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.

Key Dynamics to Monitor

ACIU profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.

ACIU carries more volatility with a beta of 1.59 — expect wider price swings.

ACIU is growing revenue faster at 1057.0% — sustainability is the question.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ACIU scores higher overall (24/100 vs 24/100) and 1057.0% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AC Immune Ltd

HEALTHCARE · BIOTECHNOLOGY · USA

AC Immune SA, a clinical-stage biopharmaceutical company, discovers, designs and develops drugs and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company is headquartered in Lausanne, Switzerland.

Visit Website →

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?